文献速递眼底病与葡萄膜炎

质子束照射治疗累及虹膜、睫状体和前部脉络膜的葡萄膜黑色素瘤:无需手术定位的光野技术

Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
PubMed 文献 · Br J Ophthalmol · 2020-12-21

该回顾性研究纳入125例在Massachusetts Eye and Ear接受质子束照射(PBI)且未行手术定位的葡萄膜黑色素瘤患者,采用光野设置。中位随访72.1个月,末次随访中位视力为20/63,复发率9.6%,继发性眼球摘除率14.4%,新生血管性青光眼发生率16.8%,转移死亡率为20.8%。结论认为该技术可获得良好保眼率和视力保留,肿瘤复发率低。

要点

  • 光野设置PBI无需手术定位,适用于后缘距锯齿缘小于两个视盘直径的肿瘤。
  • 中位随访72.1个月,复发率9.6%,继发性眼球摘除率14.4%。
  • 新生血管性青光眼发生率为16.8%,转移死亡率为20.8%。

核心结论

  • 采用光野设置质子束照射治疗累及虹膜、睫状体和前部脉络膜的葡萄膜黑色素瘤,多数病例可保眼并保留良好视力,肿瘤复发率低。

主要发现

  • 肿瘤分类:虹膜18例(14.4%)、睫状体12例(9.6%)、虹膜睫状体58例(46.4%)、睫状体脉络膜24例(19.2%)、虹膜睫状体脉络膜13例(10.4%)。
  • 69.6%的患者基线视力≥20/40,末次随访(中位随访72.1个月)中位视力为20/63。
  • 12例(9.6%)出现复发,中位复发时间治疗后4.0年,其中5例重复PBI,7例眼球摘除。
  • 18例(14.4%)行继发性眼球摘除,其中61.1%因并发症;21例(16.8%)发生新生血管性青光眼。
  • 69例治疗后诊断白内障,其中51例(73.9%)为放射性;20.8%死于转移性葡萄膜黑色素瘤,中位随访10.1年。

关键数值与推荐

  • 后缘距锯齿缘小于两个视盘直径的肿瘤采用光野技术治疗。
  • 肿瘤通过透照法和超声测量。
  • 7例抗VEGF治疗可及后发生新生血管性青光眼的患者中,5例接受玻璃体腔Avastin注射(占新生血管性青光眼患者的23.8%)。

临床怎么用

  • 对于累及虹膜、睫状体和前部脉络膜的葡萄膜黑色素瘤,可考虑采用无需手术定位的光野设置质子束照射,以保留眼球和视力。
  • 治疗后需监测复发、新生血管性青光眼和放射性白内障等并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To assess treatment outcomes after proton beam irradiation (PBI) without surgical localisation of uveal melanomas involving the iris, ciliary body and anterior choroid. METHODS: Retrospective chart review of 125 patients evaluated at Massachusetts Eye and Ear and treated with PBI using a light field set-up without localisation surgery between November 1975 and April 2017. The tumours were characterised as follows: iris (n=18, 14.4%), ciliary body (n=12, 9.6%), iridociliary (n=58, 46.4%), ciliochoroidal (n=24, 19.2%) and iridociliochoroidal (n=13, 10.4%). The tumours were measured by transillumination and ultrasonography before treatment. Tumours with posterior margin located less than two disc diameters from the ora serrata were treated using the light field technique. Patient outcomes after PBI were evaluated. RESULTS: Most patients had good vision at the time of tumour diagnosis (69.6% had baseline visual acuity (VA) of ≥20/40). Median VA at last follow-up (median follow-up: 72.1 months) was 20/63. Recurrences occurred in 12 patients (9.6%) at a median time of 4.0 years post-treatment. Recurrences were treated by repeat PBI (n=5) or enucleation (n=7). Secondary enucleation was performed in 18 patients (14.4%), and 61.1% of these were due to complications. Neovascular glaucoma (NVG) developed in 21 patients (16.8%). Of seven patients who developed NVG after anti-vascular endothelial growth factor (anti-VEGF) therapies became available, five were treated with intravitreal Avastin injections (23.8% of patients with NVG). Of 69 patients diagnosed with cataract after treatment, 51 (73.9%) were characterised as radiation-related. Death from metastatic uveal melanoma occurred in 20.8% of the cohort, with a median follow-up of 10.1 years. CONCLUSIONS: Patients treated with PBI using a light field set-up technique experience good outcomes after irradiation. Eye preservation and retention of good VA are seen in the majority of cases, and tumour recurrence is low.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Oxenreiter MM, Lane AM, Aronow MB, et al. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field). Br J Ophthalmol. 2020. PMID: 33355171. doi:10.1136/bjophthalmol-2020-318063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。